Akèy › Limfòm folikilè › Tennessee › Nashville
Etid klinik pou Limfòm folikilè nan Nashville, TN
18 etid pou Limfòm folikilè ap chèche patisipan nan sit nan ak bò kote Nashville (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Ap rekriteFaz 1/2
- Tennessee Oncology, Pllc Nashville, Nashville
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Ap rekriteFaz 1
- Sarah Cannon Research Institute - Pharmacy, Nashville
- SCRI Oncology Partners, Nashville
A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
Ap rekriteFaz 2/3
- SCRI Oncology Partners ( Site 7000), Nashville
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
Ap rekriteFaz 1/2
- SCRI Oncology Partners ( Site 0100), Nashville
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Ap rekriteFaz 1
- SCRI Oncology Partners, Nashville
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Ap rekriteFaz 1
- Sarah Cannon Research Institute, Nashville
- Vanderbilt University Medical Center, Nashville
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
Ap rekriteFaz 3
- Research Site, Nashville
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
Ap rekriteFaz 2
- Research Site, Nashville
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
Ap rekriteFaz 3
- Tennessee Oncology, Nashville
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
Ap rekriteFaz 3
- Vanderbilt University Medical Center, Nashville
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
Ap rekriteFaz 1
- Vanderbilt University/Ingram Cancer Center, Nashville
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
Ap rekriteFaz 3
- Vanderbilt-Ingram Cancer Center, Nashville
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Ap rekriteFaz 1/2
- Vanderbilt University Medical Center, Nashville
Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder
Ap rekriteFaz 2
- Vanderbilt University Medical Center, Nashville
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Ap rekriteFaz 1/2
- TriStar BMT, Nashville
This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
Ap rekriteFaz 1
- Tennessee Oncology, Nashville
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Ap rekriteFaz 1
- Tennessee Oncology, Nashville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Nashville
Etid Limfòm folikilè nan lòt vil
- New York City, NY24 etid
- Milwaukee, WI19 etid
- Houston, TX18 etid
- Boston, MA17 etid
- Baldwin Park, CA16 etid
- Seattle, WA15 etid
- Durham, NC15 etid
- Columbus, OH13 etid
- Salt Lake City, UT13 etid
- Chicago, IL12 etid
- San Antonio, TX12 etid
- Philadelphia, PA12 etid
Lòt etid nan Nashville
- Kansè Poumon ki pa ti selil97 etid
- Kansè nan tete81 etid
- Kansè Metastatik70 etid
- Kansè kolorektal69 etid
- Kansè (tout kalite)65 etid
- Kansè ovè49 etid
- Kansè pwostat43 etid
- Kansè poumon40 etid
- Karsinòm selil skuamèz tèt ak kou39 etid
- Kansè pankreyas39 etid
- Kansè Endomèt38 etid
- Melanom33 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.